FDA Drug Topics: Role of FDA and ISMP in Preventing Medication Errors
June 30, 2020
FDA
This webinar will describe the role of the Division of Medication Error Prevention and Analysis (DMEPA) in preventing and addressing medication errors through pre-market and post-market activities. DMEPA also collaborates with external stakeholders, such as the nonprofit Institute for Safe Medication Practices (ISMP), a federally authorized patient safety organization (PSO). The webinar will illustrate how information from the ISMP National Medication Errors Reporting Program is shared with FDA in a way that benefits overall drug safety. Actions taken to address recent medication error reports will be explored, as well as the role of pharmacists in identifying, preventing and mitigating medication errors.
- Draft Guidance for Industry: Best Practices in Developing Proprietary Names for Drugs: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-developing-proprietary-names-drugs.
- Draft Guidance for Industry: Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-container-labels-and-carton-labeling-design-minimize-medication-errors.
- Guidance for Industry: Safety Considerations for Product Design to Minimize Medication Errors: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-product-design-minimize-medication-errors-guidance-industry.
- Guidance for Industry: Applying Human Factors and Usability Engineering to Medical Devices: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices.
- A Lot Happens When You Report a Hazard or Error to ISMP – There’s No “Black Hole” Here! https://www.ismp.org/acute-care/medication-safety-alert-november-7-2019.
- ISMP. Start the New Year Off Right by Preventing These Top 10 Medication Errors and Hazards. https://www.ismp.org/acute-care/medication-safety-alert-january-16-2020.
- Describe FDA’s role in pre-marketing and post-marketing activities to prevent and address medication errors.
- Outline strategies aimed to increase the safe use of drug products by minimizing use error that is related to the design, naming, labeling, and/or packaging of drug products.
- Review examples of recent medication error reports.
- Summarize how HCPs can help identify, prevent, and mitigate medication errors.
This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, CPH - Certified Public Health, and physician assistants.
Day 1 June 30, 2020
Time | Topic | Speaker |
---|---|---|
1:00 - 2:00 PM EDT | FDA Drug Topics: Role of FDA and ISMP in Preventing Medication Errors |
Mishale Mistry, PharmD, MPH Michael Cohen, R. Ph |
Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Faculty
- Cohen, Michael, R. Ph, President Emeritus, ISMP - nothing to disclose
- Mistry, Mishale, PharmD, MPH, Division Director, FDA - nothing to disclose
Planning Committee
- Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- Cao, Christian, MPAS, PA-C, Cross-Discipline Safety Advisor, FDA/CDER/OSE/OPE - nothing to disclose
- De Fronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
- Kapoor, Rama, MD, Senior Physician, FDA - nothing to disclose
- Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI - nothing to disclose
CE Consultation and Accreditation Team
- Lisa Thompson, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration is complimentary; therefore refunds are not applicable.
Must attend 80% of the activity.